%0 Journal Article
%T Screening for obstructive sleep apnea in adults: US Preventive Services Task Force Recommendation Statement
%J JAMA journal of the American Medical Association
%D 2022
%A Mangione, Carol M.
%A Barry, Michael J.
%A Nicholson, Wanda K.
%A Cabana, Michael
%A Chelmow, David
%A Rucker Coker, Tumaini
%A Davidson, Karina W.
%A Davis, Esa M.
%A Donahue, Katrina E.
%A Jaén, Carlos Roberto
%A Kubik, Martha
%A Li, Li
%A Ogedegbe, Gbenga
%A Pbert, Lori
%A Ruiz, John M.
%A Stevermer, James
%A Wong, John B.
%V 328
%N 19
%P 1945-1950
%X IMPORTANCE: Current prevalence of obstructive sleep apnea (OSA) in the US is not well established; however, based on cohort and survey data, in 2007-2010 the estimated prevalence of at least mild OSA (defined as an apnea-hypoxia index [AHI] ≥5) plus symptoms of daytime sleepiness among adults aged 30 to 70 years was 14% for men and 5% for women, and the estimated prevalence of moderate to severe OSA (defined as AHI ≥15) was 13% for men and 6% for women. Severe OSA is associated with increased all-cause mortality. Other adverse health outcomes associated with untreated OSA include cardiovascular disease and cerebrovascular events, type 2 diabetes, cognitive impairment, decreased quality of life, and motor vehicle crashes. <br><br>OBJECTIVE: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for OSA in adults. POPULATION: Asymptomatic adults (18 years or older) and adults with unrecognized symptoms of OSA. EVIDENCE ASSESSMENT: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. (I statement).<p /> <p>Language: en</p>
%G en
%I American Medical Association
%@ 0098-7484
%U http://dx.doi.org/10.1001/jama.2022.20304